deoxycholate drug combination amphotericin B

01/01/2019 - "Three inhaled amphotericin B deoxycholate trials found a reduced invasive aspergillosis incidence, 1 reaching statistical significance. "
05/01/2010 - "Nebulized amphotericin B deoxycholate (n-ABD) is used to prevent Aspergillus infection in lung transplantation. "
03/01/2000 - "ABCD is approved by the US FDA for the treatment of invasive aspergillosis in patients where renal impairment of unacceptable toxicity precludes the use of amphotericin B deoxycholate in effective doses, and in patients with invasive aspergillosis where prior amphotericin B deoxycholate therapy has failed. "
11/01/2019 - "An evaluation of nebulised amphotericin B deoxycholate (Fungizone® ) for treatment of pulmonary aspergillosis in the UK National Aspergillosis Centre."
05/01/2003 - "Described here are two cases of cerebral aspergillosis successfully treated with voriconazole after the failure of first-line treatment with amphotericin B deoxycholate. "

12/22/2018 - "Amphotericin B deoxycholate for relapse visceral leishmaniasis was found to be highly effective and safe. "
08/01/2008 - "The aim of the present study was to compare the efficacy of a nano form of amphotericin B deoxycholate with that of conventional amphotericin B deoxycholate for the treatment of visceral leishmaniasis. "
11/01/2006 - "To identify and quantify the direct and indirect economic cost of treatment for visceral leishmaniasis (VL) with conventional Amphotericin B deoxycholate, currently the first-line treatment in Muzaffarpur. "
12/22/2018 - "Our study justified to include amphotericin B deoxycholate as a second line drug for visceral leishmaniasis in Bangladesh."
12/22/2018 - "Based on studies in India (as there was no studies from outside India) amphotericin B deoxycholate has been considered as a backup drug for treatment of visceral leishmaniasis. "

06/01/2006 - "Amphotericin B deoxycholate has been the 'gold standard' treatment for invasive fungal infections for over 40 years. "
10/01/2014 - "Amphotericin B deoxycholate use has increased during the past years in parallel with the increase in the number of immunosuppressed patients suffering invasive fungal infections. "
07/01/1997 - "Amphotericin B deoxycholate has remained the drug of choice for severe invasive fungal infections for nearly 40 years. "
01/15/2004 - "Continuous infusion of amphotericin B deoxycholate: a cost-effective gold standard for therapy of invasive fungal infections?"
07/15/2004 - "Early trials of empirical antifungal therapy with amphotericin B deoxycholate (AmB) documented reductions in the frequency of and the morbidity and mortality associated with invasive fungal infections. "

12/01/2006 - "In patients with invasive candidiasis, it is as effective as amphotericin B deoxycholate. "
10/01/2018 - "Amphotericin B deoxycholate (AmB-D) is standard of care treatment for neonatal invasive candidiasis (IC). "
06/01/2000 - "In persistently leukopenic mice with severe invasive candidiasis, higher dosages of both hAMB-DOC and hcAMB-DOC were tolerated than those of conventional AMB-DOC (3 versus 0.8 mg/kg of body weight, respectively), resulting in significantly improved therapeutic efficacy. "
01/01/2020 - "A randomized, double-blind trial investigating the efficacy of caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neonates and infants younger than 3 months of age."
11/01/2018 - "A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis: ERRATUM."

01/01/2019 - "Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei."
06/01/2004 - "Preceding monotherapy with amphotericin B deoxycholate 1.0-1.5 mg/kg qd had not stopped the progression of infection. "
06/01/2005 - "We describe a young patient with apparent full immune competence, who suffered from disseminated CA infection, her presentation, diagnosis and therapy with amphotericin B deoxycholate, which lead to her complete recovery and return to a productive life."
12/01/2010 - "Comparative study of the efficacy of liposomal amphotericin B and amphotericin B deoxycholate against six species of Zygomycetes in a murine lethal infection model."
12/01/2004 - "The aim of this work was to develop a murine model of cerebral infection by Scedosporium apiospermum using intracranial inoculation and to use this model to evaluate the efficacy of amphotericin B deoxycholate and liposomal amphotericin B. "